Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Damoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Bayer
- 13 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2017 Planned End Date changed from 10 Nov 2017 to 15 Dec 2017.
- 11 Oct 2017 Planned primary completion date changed from 27 Oct 2017 to 30 Nov 2017.